A randomized, open-label phase III study of first line chemotherapy in older metastatic breast cancer patients, comparing intravenous pegylated liposomal doxorubicin with oral capecitabine; and the incorporation of a complete geriatric assessment.

Trial Profile

A randomized, open-label phase III study of first line chemotherapy in older metastatic breast cancer patients, comparing intravenous pegylated liposomal doxorubicin with oral capecitabine; and the incorporation of a complete geriatric assessment.

Completed
Phase of Trial: Phase III

Latest Information Update: 12 Nov 2017

At a glance

  • Drugs Capecitabine (Primary) ; Doxorubicin liposomal (Primary)
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Acronyms OMEGA
  • Most Recent Events

    • 06 Feb 2014 Results published in the Annals of Oncology.
    • 08 Dec 2012 Results presented at the 35th Annual San Antonio Breast Cancer Symposium.
    • 24 Mar 2012 Tolerability and feasibility analysis presented at the 8th European Breast Cancer Conference.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top